CING Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Cingulate Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCING

Market Cap48.7M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Cingulate Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for [18F] Flutemetamol in Healthy (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
[18F] Flutemetamol	Healthy	n/a	Phase 3	Public pipeline row
Functional Magnetic Resonance Imaging (fMRI)	Attention Deficit Hyperactivity Disorder (ADHD) \| Impulsive Aggression	n/a	Phase 2	Public pipeline row
Gantenerumab	Alzheimer Disease	n/a	Phase 3	Public pipeline row
Magtein	Dementia \| Alzheimer's Disease	n/a	Na	Public pipeline row
Aerobic Exercise	Obesity	n/a	Na	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01265394	Phase 3	COMPLETED	218	2011-03
NCT02162524	Na	WITHDRAWN	n/a	2015-07
NCT02210286	Na	COMPLETED	17	2016-04
NCT03638466	Phase 2	TERMINATED	7	2019-11-07
NCT03444870	Phase 3	TERMINATED	1053	2022-12-28

Scientific Context

conditions | Attention Deficit Hyperactivity Disorder (ADHD) | Impulsive Aggression
conditions | Patients With Severe Mental Illness
conditions | Excessive Sleepiness
eligibility_criteria | Inclusion Criteria: * Otherwise healthy male or female subjects, aged 8-12 years, inclusive, at the time of screening with primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized US Food and Drug Administration (FDA)-approved ADHD medication. * Impulsive aggression (IA) confirmed at screening using the R-MOAS and the Vitiello Aggression Scale. Exclusion Criteria: * Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or related disorder, personality disorder, Tourette's disorder, fetal alcohol syndrome, or psychosis not otherwise specified. * Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorder. * Known or suspected IQ \<70, pregnancy, substance or alcohol abuse. * Known history of implanted brain stimulator, vagal nerve stimulator, ventriculoperitoneal shunt, cardiac pacemaker, orthodontic braces, or implanted medication port. Visual and hearing (≥25 dB) impairment. * Pre-existing medical or psychological conditions that preclude being in the MRI scanner (e.g., claustrophobia, morbid obesity, or marked anxiety about the procedure).
eligibility_criteria | Inclusion Criteria: * Healthy male or female, 18 - 45 years * Fluent and literate in English and able to provide written informed consent * BMI between 18.5 and 38.0 kg/m2 and minimum body weight of 50 kg Exclusion Criteria: * Recent exposure to any investigational product * Previous exposure to relevant fMRI task(s) * Considered medically unsuitable for participation * Has any contraindication for BOLD fMRI

Want the full CING research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.